---
title: 'Lomustine with or without reirradiation for first progression of glioblastoma,
  LEGATO, EORTC-2227-BTG: study protocol for a randomized phase III study'
date: '2024-06-07'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38849943/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240608181807&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'BACKGROUND: Chemotherapy with lomustine is widely considered as standard
  treatment option for progressive glioblastoma. The value of adding radiotherapy
  to second-line chemotherapy is not ...'
disable_comments: true
---
BACKGROUND: Chemotherapy with lomustine is widely considered as standard treatment option for progressive glioblastoma. The value of adding radiotherapy to second-line chemotherapy is not ...